FDA emergency research policy should not require disclosure of study data, attorney asserts.
EMERGENCY RESEARCH PUBLIC DISCLOSURE PROPOSAL OPPOSED by Jeffrey Gibbs of the D.C. office of Hyman, Phelps & McNamara in Nov. 6 comments on FDA's proposed policy on waiver of informed consent in emergency research. Calling for FDA to "delete" the proposed requirement for public disclosure of emergency research involving the waivers, Gibbs says that "clinical studies have historically been confidential" with "no regulatory requirement that communities be notified."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth